Nexalin publishes peer-reviewed data showing DIFS neurostimulation improves ADHD attention and normalizes brain activity
Summary
Nexalin Technology published a peer-reviewed study demonstrating that their DIFS (Deep Intracranial Frequency-Specific) cranial neurostimulation system improves attention scores and normalizes EEG-measured brain activity in ADHD patients. The published data provides clinical evidence supporting Nexalin's ongoing FDA Q-Submission process for their Gen-2 SYNC Neurostimulation Console across ADHD and Alzheimer's disease programs.
Why it matters
Peer-reviewed clinical data for a non-invasive neurostimulation approach to ADHD is valuable in a market dominated by pharmacological treatments with significant side effect concerns. The concurrent FDA Q-Submission meeting for Alzheimer's disease positions Nexalin as a dual-indication non-invasive neurostimulation platform targeting two of the largest unmet needs in cognitive medicine.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial